Adjustable IOL Maker RxSight Launches $118 Million IPO

RxSight, of Aliso Viejo, California, launched on July 30 a $118 million initial public offering of 7.35 million shares of common stock at a price of $16 per share. Shares are trading on the Nasdaq under the symbol RXST.

Study Shows Reduction in Postoperative Halos in Patients Treated With Tearscience Lipiflow Treatment Prior to Bilateral Cataract Surgery

Johnson & Johnson Vision revealed new comparative clinical study findings evaluating TearScience LipiFlow treatment in cataract surgery. The data concluded that treating patients with TearScience LipiFlow prior to cataract surgery significantly reduced patient-reports of halos compared to control group (58.6 vs. 79 percent) and showed larger improvements in Meibomian Gland Score (MGD) than control group (107 vs. 66 percent). 

Global Ophthalmic Deals Total $1.2 Billion in Q2-2021

Market Scope identified 21 ophthalmic transactions totaling nearly $1.2 billion during Q2-2021. This compares with $2.3 billion from 32 transactions in Q1-2021 and $2.3 billion from 28 transactions in Q2-2020. Funds raised included investments for the development of new products and technologies, commercialization of new products, or outright purchases of products or technologies. Transactions have ranged from $250 thousand to …